Clinical Trial

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Recruiting
View on ClinicalTrials.gov →
Summary
To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-14; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT06927648
Lead Sponsor AstraZeneca
Conditions Breast Cancer
Enrollment 130 participants
Start Date 2025-10-15
Primary Completion 2029-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07